Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities (Tables)

9 Months Ended

Sep. 30, 2020

Accrued expenses and other current liabilities consisted of the following (in thousands):


	September 30,		December 31,
	2020		2019
Accrued clinical and development expenditure	$	11,097	$	8,782
Accrued employee expenses		8,127		6,863
Other accrued expenditure		2,784		2,662
Accrued purchase commitments		2,500		5,000
Other		107		56
	$	24,615	$	23,363